Jump to main content
Jump to site search

Issue 12, 2014
Previous Article Next Article

Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo

Author affiliations

Abstract

The objective of this research is to investigate the plasma pharmacokinetics and bio-distribution of liposomal daunorubicin plus tamoxifen in breast cancer murine models through intravenous administration. Daunorubicin and tamoxifen plasma levels in pharmacokinetics studies were determined using HPLC. Biodistributions of various carriers loaded with a cyanine dye (cy7) were evaluated using in vivo imaging. After administration, free daunorubicin and tamoxifen were rapidly cleared out from the blood following a two-compartment kinetic model. The clearances and AUC (0–∞) of daunorubicin were (means ± SD): 0.028 ± 0.005 L h−1 kg−1 and 367.489 ± 56.979 μg mL−1 h−1 (liposomes), and 2.235 ± 0.347 L h−1 kg−1 and 4.546 ± 0.704 μg mL−1 h−1 (free drug). By ex vivo imaging 24 h after injection, the fluorescence intensity of liposomal cy7 plus tamoxifen in tumor region was obviously higher than that of free liposomal cy7. In conclusion, tamoxifen can improve pharmacokinetics profile of liposomal daunorubicin with enhanced therapy for breast cancer.

Graphical abstract: Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo

Back to tab navigation

Publication details

The article was received on 11 Oct 2013, accepted on 19 Dec 2013 and first published on 02 Jan 2014


Article type: Communication
DOI: 10.1039/C3TB21423K
Citation: J. Mater. Chem. B, 2014,2, 1619-1625

  •   Request permissions

    Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo

    M. H. Li, H. Yu, T. F. Wang, N. D. Chang, J. Q. Zhang, D. Du, M. F. Liu, S. L. Sun, R. Wang, H. Q. Tao, S. L. Geng, Z. Y. Shen, Q. Wang and H. S. Peng, J. Mater. Chem. B, 2014, 2, 1619
    DOI: 10.1039/C3TB21423K

Search articles by author

Spotlight

Advertisements